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Abstract This study aims to modify a cyclodextrin-PEI-
based polymer, PEI-β-CyD, with the TAT peptide for
plasmid DNA delivery to placenta mesenchymal stem cells
(PMSCs). By using the disulfide exchange between the
SPDP-activated PEI-β-CyD and TAT peptide, the TAT-PEI-
β-CyD polymer was fabricated and the success of this was
confirmed by the presence of characteristic peaks for PEI
(at δ 2.8–3.2 ppm), CyD (at δ 5.2, 3.8–4.0 and 3.4–
3.6 ppm) and TAT (at δ 1.6–1.9 and 6.8–7.2 ppm) in the 1H
NMR spectrum of TAT-PEI-β-CyD. The polymer–plasmid–
DNA polyplex could condense DNA at an N/P ratio of 7.0–
8.0, and form nanoparticles with the size of 150.6±5.6 nm
at its optimal N/P ratio (20/1). By examining the transfec-
tion efficiency and cytotoxicity of TAT-PEI-β-CyD, conju-
gation of the TAT peptide onto PEI-β-CyD was
demonstrated to improve the transfection efficiency of
PEI-β-CyD in PMSCs after 48 and 96 hours of post-
transfection incubation. The viability of PEI-β-CyD-treated
PMSCs was shown to be over 80% after 5 h of treatment
and 24 h of post-treatment incubation. In summary, this
study showed that the TAT-PEI-β-CyD polymer as a vector
for plasmid DNA delivery to PMSCs and other cells
warrants further investigations.
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1 Introduction
Stem cells have a unique capacity to differentiate into
different cell types. This renders them an unlimited source
of practical prospects in regenerative medicine [1–3].
Owing to their utility in numerous biomedical applications
[4–7], over the years stem cells have been attracting
scientific interests. Recently, the concept of nucleic acid
(NA) therapy targeting stem cells emerged, and will
potentially open a new window to medical frontiers owing
to its plausibility of tackling diseases such as Parkinson’s
disease, diabetes mellitus, and cancers [8, 9].
Thus far copious approaches have been studied for
transferring therapeutic transgenes into stem cells. As far as
correction of a genetic pathology is concerned, the stem
cells are usually meant to express therapeutic genes for the
duration of a patient life. For such purposes, it is best to use
integrating viruses (such as retroviruses and lentiviruses)
[10–12]. Alternatively, if short-term transgene expression in
stem cells is required, non-integrating vectors such as
adenoviruses or herpes simplex viruses will become more
preferable. Though viral vectors successfully deliver NA
into stem cells [8, 9], their immunogenicity and other
critical safety concerns limit their clinical applications [13,
14]. For this, extensive research efforts have been diverted
into the search of non-viral methods (such as electro-
poration and liposomes). The latest development of non-
viral NA delivery systems has recently been reviewed by
Mintzer and Simanek [15]. Despite their potential in NA
transfer, the in vivo and clinical uses of non-viral carriers
have been greatly hampered by their low transfection
efficiency and cytotoxicity [13, 14, 16–18].
Compared to other polymeric methods being explored,
cyclodextrin-based polymers attract much attention [19].
This is due to their biocompatibility, low toxicity, and non-
immunogenicity. Gonzalez et al. was the first team to report
the potential use of β-cyclodextrin (β-CyD)-containing
polymers for NA delivery [20]. Since then numerous CyD-
based NAvectors have been developed [21–23]. For details,
please refer to reviews in the published literature [19, 24].
Currently, one of the CyD-based vectors, CALAA-01,
successfully proceeds to clinical trials and provides targeted
delivery of synthetic small interfering RNA (siRNA) [21].
In view of the promise of cyclodextrin-based NA delivery
systems, a β-CyD-based polymer conjugated with low
molecular weight PEI (PEI-β-CyD) has previously been
described with reasonable transfection efficiency and low
toxicity [25]. Here, we incorporate a cell-penetrating
peptide containing the protein transduction domain (PTD)
of the HIV-1 TAT protein to form a TAT-PEI-β-CyD polymer.
As the TAT peptide was experimentally shown to promote the
rapid cellular uptake of multiple chemical entities [26, 27],
it was expected that conjugation of TAT to PEI-β-CyD
would produce a polymer that promotes the efficacy of NA
delivery into various cells. It is anticipated that conjugating
the PTD of the HIV-1 TAT peptide with the PEI-β-CyD
polymer could potentially develop a non-cytotoxic yet
effective NA delivery vehicle for meeting the needs brought
about by the emergence of stem cell technology.
2 Materials and Methods
2.1 Materials
PEI (Mw=25 kDa and 0.8 kDa), β-cyclodextrin, 1,1’-
carbodiimidazole (CDI), dimethyl sulfoxide (DMSO), β-
cyclodextrin and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). N-succinimidyl 3-(2-
pyridyldithio)propionate (SPDP) was purchased from
Pierce (USA). 13-amino acid peptide YGRKKRRQRRRPC
derived from TAT was specially ordered from Guangzhou
Jetway Biotech Co. Ltd (China). All reagents were used as
received unless otherwise specified.
2.2 Polymer Synthesis and Characterization
Synthesis of PEI-β-CyDwas carried out based on the methods
developed by Tang et al. [25]. The synthesis of PEI-β-CyD-
TATwas carried out by first allowing SPDP (3 mg, in 1.5 ml
DMSO) and PEI-β-CyD (120 mg, in 5.0 ml DMSO) to react
at room temperature for 1 h under nitrogen with constant
stirring. Peptide (21 mg, in 1.5 ml DMSO) was allowed to
react with SPDP-activated PEI-β-CyD for 3 h. After the
reaction, the reaction mixture was dialyzed with dialysis
tubing (molecular weight cut-off=12 kDa) against doubly
deionized water for 2 days and freeze dried for another 2 days.
After polymer synthesis, samples of the agent to be
tested (i.e., TAT, PEI-β-CyD or TAT-PEI-β-CyD; 1 mg)
were dissolved in 0.5 ml of D2O (Cambridge Isotope
Laboratories, Inc., MA, USA) at room temperature. The 1H
NMR spectrum of TAT, PEI-β-CyD and TAT-PEI-β-CyD
were studied by Bruker Avance 300 spectrometer
(300 MHz). Further, TAT, PEI-β-CyD and TAT-PEI-β-CyD
were studied by UV/Vis spectrometer (Lambda Bio 40). In
brief, the sample to be tested was dissolved in 1 ml of
doubly deionized water and scanned by UV–Visible
spectrometer from 200 nm to 400 nm. Cary 300 software
(Varian, Palo Alto) was employed to analyze the signals.
2.3 Polyplex Formation, Characterization and pDNA
Binding Studies
TAT-PEI-β-CyD/pDNA polyplexes were prepared as
reported by Lai and Lin [28]. In brief, the polymer solution
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(in distilled water) and DNA plasmid solution (in Tris/
EDTA buffer) were mixed in equivalent volume and at
appropriate N/P ratios. The mixture was vortexed and then
stayed at ambient conditions for 30 min before use. The
size of the TAT-PEI-β-CyD/pDNA polyplex was characte-
rized by transmission electron microscopy (TEM; Philips
CM300, Holland) with electron kinetic energy of 300 keV.
One drop of the freshly prepared complex solution was
placed onto a copper grid coated with carbon field and was
air-dried at room temperature. Further, the surface charge of
polyplexes was determined by a ZetaPALS zeta potential
analyzer (Brookhaven). Each measurement of particle size
zeta potential and was repeated ten times, and an average
value was reported.
Ethidium bromide displacement assay was performed to
study the pDNA condensing abilities of TAT-PEI-β-CyD. It
was done in which ethidium bromide (153 μl of a 0.01%
solution) was added to 96 μg of EGFP plasmids and diluted
to 6 ml. Desired concentrations of TAT-PEI-β-CyD solu-
tions were added to each well of a 96-well-microplate
respectively; 50 μl of the DNA-ethidium bromide solution
was added to obtain a final volume of 100 μl. After a 5-min
incubation, the complexes were treated with 100 μl of
distilled water. The fluorescence was measured by SPEC-
TRAFluor Plus, TECAN. Additionally, the pDNA conden-
sing abilities of TAT-PEI-β-CyD was verified by using gel
retardation assay, during which N/P ratios of 5:1, 10:1, 20:1,
30:1, 40:1, and 50:1 were first prepared. Loading buffer was
then added after polyplexes formation. It was loaded into a 1%
agarose gel with ethidium bromide and run in TAE buffer at
80 V, 60 min at room temperature. DNA bands were
visualized by a UV illuminator.
2.4 In Vitro Transfection Assay
PMSCs were harvested from three placentas (gestational
ages, 38–40 weeks) which were obtained from the Prince of
Wales Hospital in Hong Kong according to previously
established protocols [29, 30]. Tissue collections for
research were approved by the Joint Clinical Research
Ethics Committee of The Chinese University of Hong
Kong and New Territories East Cluster. The isolation of
PMSCs was in reference to the protocol reported by
Chen et al. [31]. In brief, 100 g of tissue collected from
the central placental cotyledons was cut into 1–2 mm
fragments, trypsinized (0.25% trypsin–EDTA solution;
Invitrogen, Carlsbad, CA, USA) and treated thrice with
10 U/ml DNAse I (Sigma, St Louis, MO, USA) in
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO,
Grand Island, NY, USA) at 37°C for 5 min. Afterwards,
the mixture was filtered through a 70-mm cell strainer (BD
Biosciences, San Jose, CA, USA), with the supernatants
being pooled and spun at 1,000×g for 10 min. With the
use of Percoll density gradient fractionation (1.073 g/ml,
Sigma), mononuclear cells in the medium were recovered,
and then were resuspended and seeded in a 25 cm2 flask
[32]. Cultures were maintained in DMEM (supplemented
with 10% FBS) at 37°C with 5% CO2, and medium
changes were performed every 3 days. After around 2–
3 weeks when colonies consisting of fibroblast-like cells
were observed, cells from those colonies were trypsinized
and replated for expansion under 5% CO2 at 37°C. In
order to attain single-cell-derived, clonally expanded
MSCs, second-passage cells were serially diluted and
plated in 96-well plates (Costar) at a final density of
60 cells/plate. After 1–2 weeks, colonies that exhibited
homogeneous bipolar morphology were isolated, cultured,
and expanded.
PMSCs were seeded into a 24-well plate at a density
of 2×104 per well with 0.5 ml of P-GM 24 h prior to
transfection. At the time of transfection, the medium in
each well was replaced with 200 μl of serum free DF12
medium containing TAT-PEI-β-CyD/pEGFP complexes.
After incubating for 4 h at 37°C, the medium was replaced
with 0.5 ml of fresh complete DF12 medium. The
transfection of FuGENE 6 was carried out according to
the protocol stated. The transfection efficiency of the
polymer and FuGENE 6 on PMSCs was assayed by
confocal microscopy 24, 48 and 96 h after transfection.
The cells in three random fields with the same magnifi-
cation were counted for EGFP expression.
The U87, U138, Cho, HepG2, and 293T cells were
maintained and transfected by the standard protocol as
described previously [31]. Briefly, 2×104 cells/well were
seeded on 24-well plates and allowed to incubate for
approximately 16 h in serum containing medium. At the
time of transfection, polyplexes were formed with 2 μg of
pEGFP and a desired amount of TAT-PEI-β-CyD, and were
added into the cells for a 4.5-h incubation. The trans-
fecting medium was then replaced by fresh medium.
Transfection efficiency was assayed by confocal micros-
copy 48 h after transfection. The cells in three random
fields with the same magnification were counted for EGFP
expression.
Before and after transfection, phenotypic marker
identification was performed by flow cytometry on
PMSCs. The protocol adopted was in reference to the
one reported earlier by [33]. In brief, 105 cells were
resuspended in 100 μl of PBS and incubated with primary
antibodies (anti-human CD34, CD38, CD45, CD90,
CD147 and HLA-DR) at 4°C for 1 h with 1:100 dilutions.
The labeled cells were suspended in 100 μl of PBS, and
incubated with 1 μl goat anti-mouse IgG conjugated with
FITC (Chemicon, AP124F) at 4°C for 1 h. Afterwards,
they were examined with a FACSCalibur apparatus
(Becton-Dickinson).
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2.5 MTTAssay
Desired amounts of polymers and EGFP plasmids were
mixed with the serum free medium to 200 μl to make the
polyplex solutions. PMSCs were seeded onto 96-well plates
at a density of 1×104 cells per well in 200 μl of growth
medium, incubated for 18 h to reach 75–80% confluence.
The medium was replaced with 200 μl of a polyplex
solution. After 5 h of incubation, the polyplex solution was
removed. MTT assay was performed after 24 h by a
standard protocol as described by the manufacturer. The
percentage of cell viability was calculated using the
equation ([A]test/[A]control)×100%.
3 Results
3.1 Synthesis and Characterization of TAT-PEI-β-CyD
The polymer’s synthetic pathways as well as the schematic
representation of its polyplex formation process were
illustrated in Fig. 1. The primary amine groups of PEI in
PEI-β-CyD was activated by SPDP in DMSO, followed by
their disulfide exchange with the TAT peptide, giving the
product TAT-PEI-β-CyD.
The success of the conjugation process between TAT and
the PEI-β-CyD backbone was confirmed by the chemical
shifts of PEI (2.8–3.2 ppm: –CH2CH2N–), β-CyD (H1,
5.2 ppm; H3, H5 and H6, 3.8–4.0 ppm, H2 and H4, 3.4–
3.6 ppm) and TAT (–CH2–, 1.6–1.9 ppm, aromatic protons
from TAT, 6.8–7.2 ppm) in the NMR spectrum of the
product (Supplementary Data 1). Further, the mole ratio
between PEI and β-CyD of PEI-β-CyD was calculated
from the characteristic peaks of PEI (–CH2CH2NH–; at δ
2.3–2.8 ppm) and C-1 hydrogen in β-CyD. It was
approximated to be 1:1.1. In UV–Visible light spectrometry,
PEI-β-CyD did not show any absorption around 285 nm,
while both TAT and TAT-PEI-β-CyD showed large absorp-
tion peaks at 285 nm (Fig. 2a).
3.2 Polyplex Formation and Characterization
The particle sizes of TAT-PEI-β-CyD/DNA polyplexes were
estimated by TEM, and found to be larger than that of PEI-
β-CyD/DNA polyplex at the range of N/P ratios examined
(from 5/1 to 50/1). The size of the TAT-PEI-β-CyD polyplex
(N/P ratio=20) was estimated to be of 150.6±5.6 nm
(Fig. 2b), with relatively narrow and unimodal size
distributions ranging from 150 to 200 nm.
The zeta potentials of TAT-PEI-β-CyD/DNA polyplexes
at different N/P ratios were found to be lower than that of
PEI-β-CyD polyplexes (Fig. 2c). In addition, the zeta
potentials of TAT-PEI-β-CyD/DNA polyplexes were posi-
tive at all N/P ratios tested, with the value being higher than
+20 mVat the N/P ratios over 20/1.
Having high DNA condensing ability is an important
factor for a successful polymeric gene delivery system. By
the ethidium bromide displacement assay, TAT-PEI-β-CyD
was shown to completely retard DNA at N/P ratios 7.0–8.0
(Fig. 2d), and had similar DNA condensation ability to PEI-
β-CyD as demonstrated by gel retardation (Supplementary
Data 1).
3.3 Transfection and Cytotoxicity
As shown in Fig. 3, the transfection efficiency of TAT-PEI-
β-CyD (N/P ratio=20, 48-h post-transfection incubation) in
Fig. 1 a Reaction scheme of the synthesis of TAT-PEI-β-CyD. b
Schematic representation of the structure of TAT-PEI-β-CyD and the
polyplex formation by TAT-PEI-β-CyD and plasmid DNA
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U87, U138, and 293T reached 50–80%, while in Cho and
HepG2, 34–40% was reached. Importantly, we observed
good transfectability of the polymer in PMSCs. According
to Fig. 4a, TAT-PEI-β-CyD not only has transfection
efficiency (as determined by the percentage of cells
exhibiting green fluorescence) around twice that of PEI-β-
CyD after 48 and 96 h of post-transfection incubation, but
also achieved more sustained transgene expression as
compared to PEI-β-CyD. With immunophenotyping, sim-
ilar expression profiles (including positivity for CD147 and
CD90, but negativity for CD34, CD38, CD45 and HLA-
DR) in the PMSCs before and after transfection were
observed (data not shown). This demonstrated the mainte-
nance of multipotency of PMSCs before and after TAT-PEI-
b-CyD-mediated transfection.
In the MTTassay performed on PMSCs, the cytotoxicity
of TAT-PEI-β-CyD was found to be dose dependent. At a
concentration up to 45 nM of TAT-PEI-β-CyD, no statisti-
cally significant cytotoxicity was observed in PMSCs
(Fig. 4b). Such low cytotoxicity is comparable to that of
unmodified low molecular weight PEI and PEI-β-CyD as
previously reported [25].
4 Discussion
Cyclodextrins (CyDs) are cyclic (α-1,4)-linked oligosac-
charides of α-D-glucopyranose. They contain hydrophobic
central cavities and hydrophilic outer surfaces. Common
types of CyDs include α-, β-, and γ-CyDs. They consist of
six, seven and eight D-glucopyranose units, respectively.
Due to their low toxicity, lack of immunogenicity, and
ability to form inclusion complexes with a variety of guest
molecules in solution and in solid state, CyDs have been
extensively used as carriers to improve the solubility,
stability, and bioavailability of chemical drugs [22]. Davis
and colleagues modified the CyD structurally to make it
possessing amine groups, granting it potential of being
served as part of the backbone of other linear polymers
[20]. Their polymer, CALAA-01, was finally developed as
an experimental therapeutic that provides targeted delivery
of synthetic siRNA in humans [21]. Numerous other CyD-
containing polymeric gene vectors have now been devel-
oped [34, 35]. The majority of them are CyD dependent
polymers with a polycation skeleton [22]. These polymers
generally displayed improved transfection efficiency and
lower toxicities when compared to their non-modified
counterparts. Similar improvements in terms of transfection
efficiency were also demonstrated in viral vectors upon
CyD conjugation [36–38]. The mechanism underlying such
an improvement is not clear. It is possible that CyDs can
complex with phospholipids and cholesterols, thereby
Fig. 3 The transfection efficacy of TAT-PEI-β-CyD in various cell lines
(N/P=20, 4.5-h transfection and 48 h post-transfection incubation)
Fig. 2 a UV spectrum of TAT-
PEI-β-CyD, PEI-β-CyD, and
TAT peptide. The increase in
absorption at 285 nm indicates
the successful conjugation of
TAT peptide to PEI-CyD; b
Electron micrograph of TAT-PEI-
β-CyD/pEGFP complexes.
White bar is 200 nm. c Zeta
potential of TAT-PEI-β-CyD/
pEGFP polyplexes at different
N/P ratios. d Ethidium bromide
displacement assay of PEI-β-
CyD/pEGFP compared with
TAT-PEI-β-CyD/pEGFP
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disrupting biological membranes and assisting cellular
uptake and/or intracellular trafficking of DNA.
Stem cells are difficult to transfect. Developing an
efficient and non-toxic vector for pDNA transfer to stem
cells would be of technical and practical importance. In
our study human mesenchymal stem cells (MSCs) were
used because their extraction raises less ethical concerns
as compared to that of embryonic stem (ES) cells [39].
Further, because of their high proliferation potential and
their abilities to differentiate into multiple lineages as well
as to engraft onto numerous organs [32, 39, 40], MSCs
have long been investigated as a therapeutic tool for
biomedical applications, ranging from enhancement of
angiogenesis in ischemic limbs [41] to tissue regeneration
[42]. Their therapeutic appeal has been further promoted
by recent reports which suggested that MSCs could
potentially be used as “off-the-shelf” cells due to their
immunotolerance properties [43]. The therapeutic efficacy
of MSCs rely on their homing ability and their capacity to
synthesize and secret the therapeutic proteins [10, 41, 44].
The development of a viable NA carrier for MSCs would
be potentially of clinical importance.
Our backbone polymer, PEI-β-CyD, is a safe and
efficient polyplex-forming agent for both in vitro and in
vivo pDNA transfection. It has previously been successful-
ly conjugated with folic acid and demonstrated good
transfection efficiency in cancer cells [45]. Here, we
incorporated the PEI-β-CyD copolymer with the TAT
peptide and tested its efficacy as a polymeric vector for
pDNA delivery to stem cells. The PTD of the HIV-1 the
TAT peptide could promote the cellular uptake of fusion
proteins and other covalently linked small molecules into
the cytoplasm [26, 27]. A 13-amino acid peptide
(YGRKKRRQRRRPC derived from TAT(47–57) with a C
residue added to the C-terminal to facilitate conjugation)
was conjugated to the PEI-β-CyD polymer to produce TAT-
PEI-β-CyD. The structure of the TAT-PEI-β-CyD was
characterized by UV spectrophotometry (Fig. 2a). TAT
exhibited an absorption peak at 285 nm due to the aromatic
ring on its tyrosine residue. The presence of this peak in the
spectrum of TAT-PEI-β-CyD but not PEI-β-CyD suggested
the successful conjugation of TAT to PEI-β-CyD. Such an
observation was further confirmed by the 1H NMR
spectrum of TAT-PEI-β-CyD which exhibited characteristic
peaks for PEI (δ 2.8–3.2 ppm, –CH2CH2N– protons of
PEI), CyD (δ 5.2 ppm, H1 of β-CyD, δ 3.8–4.0 ppm, H3,
H5, and H6 of β-CyD, δ 3.4–3.6 ppm, H2 and H4 of β-
CyD) and TAT (δ 1.6–1.9 ppm, –CH2– protons of TAT, δ
6.8–7.2 ppm, aromatic protons of TAT; Supplementary Data
1). Though it may be argued that similar UV and NMR
spectra as those from Fig. 2a and Supplementary Data 1
could also be obtained by physical mixtures of TAT and the
copolymer PEI-β-CyD; however, this possibility is minimal
because unreacted TAT is expected to be removed com-
pletely by dialysis with dialysis tubing (molecular weight
cut-off=12 kDa) against water. The TAT peptide that
remains is expected to have been attached covalently to
PEI-β-CyD. Despite this, in case further confirmation of
the covalent insertion of the TAT peptide on PEI-β-CyD is
Fig. 4 a (i) Representative fluorescence and phase contrast micro-
graphs of PMSCs captured 96 h after EGFP transfection (at N/P=20)
mediated by TAT-PEI-β-CyD/pEGFP in the absence of 10% FBS. (ii)
Time course study of transfection efficiency of TAT-PEI-β-CyD/
pEGFP and PEI-β-CyD/pEGFP on PMSCs. b MTT assay in PMSCs.
Cells were treated with PEI 25 kDa, PEI 0.8 kDa, PEI-β-CyD and
TAT-PEI-β-CyD, respectively
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required for future research, employment of more sophis-
ticated approaches such as mass spectroscopy for further
characterization may be helpful.
As judged by the EGFP transfection assay, we
observed that TAT-PEI-β-CyD has much higher transfec-
tion efficiency in PMSCs after 48 and 96 h of post-
transfection incubation (Fig. 4a). This may pertain to the
facilitation of cellular uptake of the pDNA polyplexes
after the incorporation of the TAT peptide into the
polymeric vector. Further, low cytotoxicity is an important
criterion for a successful gene delivery system. Based on
the MTT assay, we have recognized that TAT-PEI-β-CyD
was non-toxic at its working concentrations (at an N/P
ratio of 20) on PMSCs, on which over 80% of cell
viability was maintained (Fig. 4b).
For future research, various polymeric modifiers can be
applied to promote the transfection efficiency of the
polymer towards PMSCs. The compositional ratio of PEI,
β-CyD and TAT is also worth further optimization to fine-
tune the structure of the polymer to the best possible
transfection capacity. Here, it is worth noting that different
types of stem cells might react differently towards TAT-PEI-
β-CyD-mediated transfection, causing the resultant efficacy
to be varied. To confirm the actual applicability of the
polymer in individual types of stem cells, specific in vitro
studies are required. In addition, earlier studies recognized
that different states (such as cell cycle states) of stem cells
may restrict or alter the expression efficiency of the
transgene delivered by cationic lipids [46]. However, how
those factors could associate with the efficiency of
polymeric stem cell transfection (especially those mediated
by TAT-PEI-β-CyD) was ill-defined. Clarification of this
issue could help to optimize the working conditions for
polymer-mediated stem cell transfection, and to improve
the efficiency thereof. Such information would be valuable
to future research on stem cell therapy ex vivo, in vivo or
even clinically.
5 Conclusions
An efficient yet non-cytotoxic vector is a sine qua non in
NA therapy. At present, numerous NA carriers for cancer
cells have been developed, yet efficient polymeric vectors
for NA delivery into stem cells are heavily lacking. In fact,
stem cells have presented themselves as being difficult to be
transfected. This is also one of the biggest technical
challenges in NA delivery research to date. This study
demonstrates the feasibility of using TAT-PEI-β-CyD for the
efficient transfer of pDNA into PMSCs while preserving
multipotency and achieving high cell viability. It is
anticipated that this polymer can be further developed into
a non-viral NA delivery cargo for stem cells.
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